2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1115 Ravulizumab efficacy and safety in complement inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria in China: A phase 3, open-label, multicenter study

Ziwei Liu, MD, Qin Guo2, Hanjun Wu3, Jing Song4, Bing Han5
1 Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2 AstraZeneca Global R&D China Center, Shanghai, China
3 AstraZeneca Global R&D China Center, Shanghai, China
4 AstraZeneca Global R&D China Center, Shanghai, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Introduction

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by terminal complement-mediated intravascular hemolysis, which is associated with increased risks of thromboembolic events, morbidity and premature mortality. Ravulizumab, a second-generation, long-acting C5 inhibitor engineered from eculizumab is the current standard of care for patients (pts) with PNH. Global trials have shown that ravulizumab led to avoidance of breakthrough hemolysis and normalization of lactate dehydrogenase (LDH) levels in PNH, but limited evidence is available in Chinese pts.

Methods

This phase 3, single-arm, open-label, multicenter study (NCT06578949) enrolled adults with confirmed PNH in China, who had LDH ≥1.5× upper limit of normal (ULN), and were complement inhibitor-naïve. Pts received weight-based intravenous ravulizumab, with a loading dose (2400, 2700, and 3000 mg for ≥40 to <60, ≥60 to <100, and ≥100 kg, respectively) on day 1, followed by maintenance dosing (3000, 3300, 3600 mg, respectively) every 8 weeks (Q8W) starting on day 15, over a 58-week treatment period (comprising 26-week primary treatment period and 32-week extension treatment period). The primary endpoint was the percentage change from baseline in LDH to week 26; key secondary endpoints included the proportion of patients achieving LDH <1.5× ULN, transfusion avoidance, and breakthrough hemolysis through week 26, as well as change in hemoglobin (Hgb) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score from baseline to week 26. Pharmacokinetic/pharmacodynamic outcomes included serum ravulizumab concentrations and change in serum free C5 over time. Safety outcomes included incidence of adverse events (AEs) and serious AEs (SAEs). All enrolled pts who received at least 1 dose of ravulizumab were included in the analyses.

Results

Of 20 pts screened, 18 were enrolled and received ravulizumab treatment. Mean (standard deviation [SD]) age was 42.8 (10.4) years; 83.3% were male. Mean (SD) baseline LDH level was 1774.8 (518.7) U/L and 11.1% had a history of major adverse vascular events. ravulizumab significantly reduced LDH at week 26 (least squares mean percentage change from baseline, -81.3%; 95% confidence interval [CI], -84.2 to -78.3; p < 0.001), with 94.1% pts achieving LDH <1.5× ULN. Through week 26, 94.4% of pts achieved transfusion avoidance and no pts had breakthrough hemolysis. Improvements in anemia (mean change from baseline in Hgb, 26.6 g/L; 95% CI, 13.8 to 39.3) and quality of life (mean change from baseline in FACIT-Fatigue score, 4.5; 95% CI, 1.3 to 7.7) were also observed. All the efficacy parameters were maintained through the end of the study. After ravulizumab initiation, steady-state serum ravulizumab concentration was rapidly achieved and remained stable through 58 weeks; immediate, complete, and sustained inhibition of serum free C5 (terminal complement) was achieved throughout the entire treatment period with Q8W dosing. In total, 88.9% had ≥1 AE (all grade 1/2), with headache being the most common (38.9%), followed by upper respiratory tract infection (22.2%) and diarrhea (16.7%). Two pts (11.1%) had 1 SAE each, and both SAEs were investigator-assessed as not related to ravulizumab. There were no AEs leading to ravulizumab discontinuation, no thromboembolic events, and no deaths or meningococcal infections reported.

Conclusions

Ravulizumab significantly reduced LDH levels (with the majority of patients achieving LDH <1.5× ULN) at week 26, indicating effective control of intravascular hemolysis, in Chinese pts with PNH. Improvements in anemia, fatigue and transfusion avoidance were also observed. Ravulizumab demonstrated a well-established and manageable safety profile, consistent with the extensive body of evidence accumulated across clinical studies and real-world use. Overall, our results support the use of ravulizumab in Chinese pts with PNH.

Bing Han: No relevant conflicts of interest to declare.